{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"18.53","upperLimit":"41.82","value":"21.82"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"70"}],"units":"Participants"}],"description":"Median PFS time equals the time of randomization (in months) until disease progression, death from any cause, or protocol deviation due to lenalidomide dosing (above 10mg), whichever occurs first.","dispersionType":"Inter-Quartile Range","groups":[{"description":"Patients receive activated Marrow Infiltrating Lymphocytes (aMIL)\n\naMIL: On day 0, patients will receive auto transplant followed by Tadalafil and aMIL. At day 60, patients will receive Lenalidomide.","id":"OG000","title":"aMIL Arm"}],"paramType":"MEDIAN","populationDescription":"This is an analysis by intention-to-treat and only considers transplanted patients randomized to the aMILs arm.","reportingStatus":"POSTED","timeFrame":"5 years","title":"Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}